Cupid shares have surged 617% over the past year, reaching a fresh 52-week high of ₹313.90 following the company's latest guidance revision. As per The Economic Times, this follows a remarkable 195% year-to-date gain and 10.66% monthly rise, making it one of the most consistent multibagger performers in the market. The stock's phenomenal rally has lifted the company's market capitalization to around ₹19,381 crore, with retail investors benefiting significantly as they collectively held a 52.8% stake at the end of the June quarter. More than 2 lakh shareholders with share capital of up to ₹2 lakh held a combined 13.81% stake as of the March quarter, according to Trendlyne data.
Cupid shares jumped to a fresh 52-week high on Thursday after the condom-maker announced its second increase in profit and revenue guidance in less than two weeks. As per The Economic Times, the company now expects to post revenue of ₹800 crore and net profit of ₹250 crore in FY27, representing a significant upward revision from its previous guidance. This comes after the company last week raised its FY27 revenue guidance to ₹725-750 crore and net profit guidance to ₹210-225 crore. The company has raised its revenue guidance by up to 10% and profit guidance by up to 19% in less than two weeks, driven by strong Q2 FY27 business momentum expected to continue through Q3 and Q4 FY27.
Cupid continues to witness strong business momentum in FY27, with Q2 FY27 total revenue expected to cross ₹200 crore, as reported by The Economic Times. The company attributed the revised guidance to sustained momentum across its key business verticals and improved visibility across domestic and international markets. The FY27 outlook is supported by strong Q2 FY27 business momentum expected to continue and grow through Q3 and Q4 FY27, improved visibility across institutional and private markets, continued expansion of the domestic FMCG business, progress towards imminent operationalisation of the Palava facility, and sustained growth across the company's healthcare and personal care portfolio.
As reported by The Economic Times, Cupid aims to strengthen its international healthcare business by expanding institutional, government and private-market opportunities across geographies, as well as build regional manufacturing platforms through the proposed South African venture. This creates a potential base for wider international market expansion. The company also plans to explore strategic healthcare opportunities through partnerships and investments that complement Cupid's healthcare and personal care ecosystem. The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits, with operations spanning more than 125 countries where exports rose to ₹208 crore, accounting for nearly 60% of revenue during FY26.
According to Prithvi Finmart's Harish Jujarey, Cupid stock has been consolidating in the 255-295 range for the past two months before breaking out with strong volumes. The analyst notes that upside targets are placed at ₹335-350 based on the range breakout, while 275, which coincides with the 20-day EMA, is expected to act as a strong support. As per The Economic Times, the stock recently got added to the Nifty Smallcap 250 index, with the company delivering massive long-term returns of more than 7,521% in three years and 13,335% in five years. The company continues to be driven by its two complementary businesses - global healthcare and Bharat consumer business, with the stock gaining nearly 1% to ₹313.90 apiece on NSE on Thursday following the latest guidance announcement.
